DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Plasma Determination of Glucagon-Like Peptide 2 as a Predictor of Recovery in Adults With Acute Intestinal Failure

Information source: Imperial College London
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Short Bowel Syndrome

Phase: N/A

Status: Recruiting

Sponsored by: Imperial College London

Official(s) and/or principal investigator(s):
Alastair Forbes, Principal Investigator, Affiliation: University College London Hospitals

Overall contact:
Katharina Wallis, Email: katharina.wallis@ic.ac.uk


The purpose of this study is to investigate the theory that the plasma level of Glucagon like peptide 2 (GLP-2) in patients with intestinal failure can predict their clinical recovery.

Clinical Details

Official title: Plasma Determination of Glucagon-Like Peptide 2 as a Predictor of Recovery in Adults With Acute Intestinal Failure

Study design: Observational Model: Defined Population, Time Perspective: Longitudinal

Detailed description: When major segments of small bowel have been removed surgically, or damaged by disease, the length of the residual bowel may be inadequate to maintain overall nutrition and the net result is described as "intestinal failure". Without medical intervention, patients with intestinal failure become malnourished and dehydrated because their remaining intestine is unable to absorb enough water, vitamins and other nutrients from the ingested food. Intravenous feeding offers life saving treatment but causes complications like infections and liver problems. It also poses enormous strain on day to day life. Glucagon like peptide 2 (GLP-2) is a naturally occurring hormone (or chemical messenger) that is able to increase the surface area of the intestinal lining (or mucosal mass) and the absorptive efficiency of the remaining intestine. Intestinal failure patients in whom not only parts of the small bowel but also the large bowel have had to be surgically removed have been shown to have a markedly impaired rise in GLP-2 levels following meals, in contrast to patients with a preserved large bowel who have increased levels of GLP-2 and are known to have much better functional adaptation. From this we hypothesise that the GLP-2 level is directly related to, and could predict, clinical recovery in intestinal failure as measured by Amount of parenteral nutrition required Length of hospital stay Mortality We also aim to compare GLP-2 levels of patients with acute intestinal failure with that of patients with chronic intestinal failure as well as healthy controls


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Men and woman, aged 18 years of age or older at the time of signing the informed

consent form.

- Referral to or direct admission to St. Mark's Hospital.

- Acute intestinal failure resulting in TPN dependency as a result of major intestinal

resection performed during admission to St. Mark's or at the referring hospital. Exclusion Criteria:

- Inability to give consent or comply with the study.

- Inability to take test meal (unable to be tested)

- Severe renal impairment (interference with GLP-2 excretion)

- Severe uncorrected anaemia (preventing additional blood-letting)

- Uncontrolled diabetes mellitus (risk of hyperglycaemia)

Locations and Contacts

Katharina Wallis, Email: katharina.wallis@ic.ac.uk

St Mark's Hospital, Harrow, Middlesex HA1 3UJ, United Kingdom; Recruiting
Katharina Wallis, MD, Phone: 0044 797 101 4634, Email: katharina.wallis@ic.ac.uk
Katharina Wallis, MD, Sub-Investigator
Additional Information

Web site devoted to the study of the glucagon-like peptides

Starting date: February 2005
Last updated: September 12, 2005

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017